January 30, 2015
In a phase 2b clinical trial, a regimen of daclatasvir combined with pegylated interferon alfa-2a and ribavirin was safe and generally well tolerated among patients with hepatitis C virus genotype 2 and 3 infections, as well as reduced the duration of treatment, according to study data.
Researchers randomly assigned 151 patients with HCV genotype 2 (n=71) or 3 (n=80) infection to 60 mg daclatasvir (Bristol-Myers Squibb) for 12 or 16 weeks or placebo for 24 weeks, both combined with PEG-IFN a-2a and ribavirin. Fifty patients were in the 12-week group, 50 were in the 16-week group and 51 received placebo. Treatment duration was extended to 24 weeks if patients did not achieve an early virologic response.